ASTEC

Astec Lifesciences Share Price

₹1,050.50 -4.95 (-0.47%)

21 Nov, 2024 14:38

SIP TrendupStart SIP in ASTEC

Start SIP

Performance

  • Low
  • ₹1,051
  • High
  • ₹1,060
  • 52 Week Low
  • ₹825
  • 52 Week High
  • ₹1,474
  • Open Price₹1,056
  • Previous Close₹1,055
  • Volume5,728

Investment Returns

  • Over 1 Month -3%
  • Over 3 Month -12.81%
  • Over 6 Month -10.05%
  • Over 1 Year -15.09%
SIP Lightning

Smart Investing Starts Here Start SIP with Astec Lifesciences for Steady Growth!

Invest Now

Astec Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -19.9
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 2,060
  • P/B Ratio
  • 5.6
  • Average True Range
  • 28.64
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -18.66
  • RSI
  • 39.95
  • MFI
  • 37.19

Astec Lifesciences Financials

Astec Lifesciences Technicals

EMA & SMA

Current Price
₹1,050.50
-4.95 (-0.47%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹1,076.01
  • 50 Day
  • ₹1,116.01
  • 100 Day
  • ₹1,151.03
  • 200 Day
  • ₹1,178.56

Resistance and Support

1058.57 Pivot Speed
  • R3 1,074.93
  • R2 1,070.52
  • R1 1,062.98
  • S1 1,051.03
  • S2 1,046.62
  • S3 1,039.08

What's your outlook on Astec Lifesciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Astec Lifesciences Ltd. manufactures agrochemical products, including fungicides, herbicides, and intermediates. With advanced production facilities in India, it serves agricultural sectors globally, offering high-quality crop protection solutions to enhance farm productivity and sustainability.

Astec Lifesciences has an operating revenue of Rs. 372.46 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -13% needs improvement, ROE of -12% is poor and needs improvement. The company has a debt to equity of 54%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 1 which is a POOR score indicating inconsistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 45 indicates it belongs to a fair industry group of Chemicals-Agricultural and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Astec Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-07-29 Quarterly Results
2024-05-02 Audited Results
2024-01-25 Quarterly Results
2023-10-27 Quarterly Results & Others

Astec Lifesciences F&O

Astec Lifesciences Shareholding Pattern

66.75%
4%
0.53%
0%
21.94%
6.78%

About Astec Lifesciences

  • NSE Symbol
  • ASTEC
  • BSE Symbol
  • 533138
  • ISIN
  • INE563J01010

Similar Stocks to Astec Lifesciences

Astec Lifesciences FAQs

Astec Lifesciences share price is ₹1,050 As on 21 November, 2024 | 14:24

The Market Cap of Astec Lifesciences is ₹2060.2 Cr As on 21 November, 2024 | 14:24

The P/E ratio of Astec Lifesciences is -19.9 As on 21 November, 2024 | 14:24

The PB ratio of Astec Lifesciences is 5.6 As on 21 November, 2024 | 14:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23